Nanobiotix plans head and neck cancer treatment trial

By staff writers

January 8, 2020 -- Nanotech radiation therapy technology developer Nanobiotix said it will launch a trial for its NBTXR3 nanoparticle for use in treating late-stage head and neck cancers.

NBTXR3 initially received the European CE Mark for treatment of locally advanced soft-tissue sarcoma, and the company said it is now focusing on applying the nanoparticle to the treatment of head and neck cancers.

In addition, the firm said that it's evaluating the use of NBTXR3 in immuno-oncology. Nanobiotix's collaborators -- the University of Texas MD Anderson Cancer Center in Houston and PharmaEngine in Asia -- also are continuing to develop the nanoparticle for other indications, such as lung, esophageal, pancreatic, and other cancers, the company said.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking